报价延迟最少15分钟:2025/07/21 08:32 EDT
盘前时段
|
||||
|
9.2078 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
9.02
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-3.61/-4.29
|
|
企业价值
1.35B
|
| 资产负债 |
|
每股账面净值
4.73
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/07/21 08:32 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401. |
